# Pre-Mortem Gate: Barclays PLC

## Bank Profile
- **Institution**: Barclays PLC
- **Headquarters**: London, United Kingdom
- **Primary Regulator**: FCA/PRA (UK)
- **Phase**: 1 (European Tier 1)
- **Execution Tier**: A (Full protocol)

## Pre-Mortem Analysis

### If This Research Fails to Reach a Definitive Classification, the Likely Causes Would Be:

#### 1. Visibility vs. Action Conflation
- **Risk**: Lee Braine's high visibility in CDM/blockchain discourse could create impression of firm-level commitment without corresponding production evidence
- **Mitigation**: Explicitly distinguish personal advocacy from institutional deployment decisions
- **Signal to watch**: Barclays corporate announcements vs. Lee Braine conference talks

#### 2. FINOS Contributor Ambiguity
- **Risk**: "Contributor" status covers a wide spectrum from minor bug fixes to major architectural contributions
- **Mitigation**: Search for specific GitHub commits, maintainer roles, and contribution scope
- **Signal to watch**: Named contributions, commit history, maintainer status

#### 3. UK DRR Context Confusion
- **Risk**: 2018 BOE/FCA pilot participation doesn't indicate current status (7 years ago)
- **Mitigation**: Focus on 2023-2024 evidence; treat 2018 as historical baseline only
- **Signal to watch**: UK EMIR September 2024 response, recent regulatory engagement

#### 4. European vs. UK Regulatory Divergence
- **Risk**: Post-Brexit, UK EMIR and EU EMIR have diverged; need to track UK-specific compliance
- **Mitigation**: Search for UK EMIR Refit specifically, not just "EMIR"
- **Signal to watch**: UK-specific regulatory announcements

#### 5. Derivatives vs. Banking Scope
- **Risk**: Barclays has large retail and investment banking; CDM relevance varies by unit
- **Mitigation**: Focus on Barclays Investment Bank and derivatives trading units
- **Signal to watch**: Which business units are mentioned in CDM context

### Prior Probability Assessment

| Factor | Adjustment | Rationale |
|--------|------------|-----------|
| Base Rate | 25% | Standard large bank baseline |
| Derivatives-Dominant | +10% | Major derivatives desk |
| Confirmed FINOS Contributor | +20% | Baseline Architect-Follower |
| **Total Prior** | **55%** | Elevated but not conclusive for Leader |

### Key Questions for This Research

1. **Production vs. Pilot**: Has Barclays moved any CDM implementation into production?
2. **Governance Role**: Does Barclays hold CDM governance positions (ISDA board, FINOS steering)?
3. **Technical Leadership**: Is Barclays a CDM maintainer or major contributor?
4. **UK EMIR Response**: How did Barclays respond to September 2024 UK EMIR changes?
5. **Lee Braine Transition**: Is Lee Braine's advocacy translating to institutional commitment?

### Evidence Categories to Populate

| Category | Leader Evidence | Follower Evidence |
|----------|-----------------|-------------------|
| Production | Live CDM deployment | Only pilots/PoCs |
| Governance | Board/committee seats | Participant only |
| Technical | Maintainer/major contributor | Minor contributions |
| Regulatory | CDM-based compliance | Traditional compliance |
| Ecosystem | Leading initiatives | Following initiatives |

### Null Hypothesis

**H0**: Barclays remains at ARCHITECT-Follower level with advocacy outpacing implementation

**H1**: Barclays has upgraded to ARCHITECT-Leader with production, governance, or technical leadership evidence

### Potential Confirmation Biases to Avoid

1. **Halo Effect**: Lee Braine's reputation shouldn't inflate firm classification
2. **Conference Talk Weighting**: Speaking engagements =/= production deployment
3. **Historical Assumption**: 2018 pilot participation doesn't prove current commitment
4. **UK Leadership Bias**: Being UK-headquartered near regulators doesn't mean leading adoption

### Success Criteria for Research Completion

- [ ] Clear production OR non-production status determination
- [ ] Governance role confirmation/denial
- [ ] Lee Braine activity mapped to institutional outcomes
- [ ] UK EMIR 2024 response characterized
- [ ] Confidence interval narrowed to actionable range

---

**Pre-Mortem Gate Status**: PASS - Research objectives clearly defined, biases identified

**Proceed to**: Tier 1 Evidence Collection
